Process engineering of natural killer cell-based immunotherapy
Trends in Biotechnology · 2023-10 · 41 (10) · 1314-1326
DOI: 10.1016/j.tibtech.2023.03.018 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Trends in Biotechnology, 2023-10. Verfasst von Pedram Motallebnejad und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemical Engineering and Materials Science, University of Minnesota, Minneapolis, MN 55455, USA. Hauptthemen laut MEDLINE: Immunotherapy, Adoptive, Neoplasms. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 82 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS, National Science Foundation, National Institutes of Health.
Abstract (Originalsprache)
Cell therapy offers the potential for curative treatment of cancers. Although T cells have been the predominantly used cell type, natural killer (NK) cells have attracted great attention owing to their ability to kill cancer cells and because they are naturally suitable for allogeneic applications. Upon stimulation by cytokines or activation by a target cell, NK cells proliferate and expand their population. These cytotoxic NK cells can be cryopreserved and used as an off-the-shelf medicine. The production process for NK cells thus differs from that of autologous cell therapies. We briefly outline key biological features of NK cells, review the manufacturing technologies for protein biologics, and discuss their adaptation for developing robust NK cell biomanufacturing processes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Chemical Engineering and Materials Science, University of Minnesota, Minneapolis, MN 55455, USA.
- Bluebird Bio, Cambridge, MA 02142, USA.
- Department of Medicine, University of Minnesota, Minneapolis, MN 55455, USA.
- Department of Chemical Engineering and Materials Science, University of Minnesota, Minneapolis, MN 55455, USA. Electronic address: wshu@umn.edu.
Förderung
- NHLBI NIH HHS
- National Science Foundation
- National Institutes of Health
Zitieren
APA
Motallebnejad, P., Kantardjieff, A., Cichocki, F., Azarin, S. M., & Hu, W. S. (2023). Process engineering of natural killer cell-based immunotherapy. Trends in Biotechnology, 41(10), 1314-1326. https://doi.org/10.1016/j.tibtech.2023.03.018
Vancouver
Motallebnejad P, Kantardjieff A, Cichocki F, Azarin SM, Hu WS. Process engineering of natural killer cell-based immunotherapy. Trends in Biotechnology. 2023;41(10):1314-1326. doi:10.1016/j.tibtech.2023.03.018
BibTeX
@article{Motallebnejad2023,
author = {Motallebnejad, Pedram and Kantardjieff, Anne and Cichocki, Frank and Azarin, Samira M and Hu, Wei-Shou},
title = {Process engineering of natural killer cell-based immunotherapy},
journal = {Trends in Biotechnology},
year = {2023},
volume = {41},
number = {10},
pages = {1314--1326},
doi = {10.1016/j.tibtech.2023.03.018}
}
EUVIMED